CpGOligodeoxynucleotide Market, by Source (Natural Source and ChemicalSynthesis), by End User (Research Institutes, Hospitals, Contract ResearchOrganizations, Pharmaceutical Companies, and Others), and by Geography (NorthAmerica, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size,Share, Outlook, and Opportunity Analysis, 2018 – 2026
CpG oligodeoxynucleotide (CpGODN) is a synthetic oligodeoxynucleotide, which contains unmethylated CpGmotifs derived from bacterial DNA with immunostimulatory activities. CpG ODN isa short single-stranded synthetic DNA molecule, which contains one of each ofcytosine triphosphate deoxynucleotide and guanine triphosphate deoxynucleotidethat makes up the C component in the molecule.
The CpG motifs are consideredpathogen-associated molecular patterns (PAMPs), as they are present in microbialgenomes in abundance, but are rarely present in vertebrate genomes. These CpGPAMPs are recognized by the pattern recognition receptor (PRR) toll-likereceptor 9 (TLR9), which is constitutively expressed only in B cells andplasmacytoid dendritic cells (pDCs) in humans and other higher primates. CpGODNs show great potential for attachment in prophylactic vaccines designed toprevent infection. Various research companies are targeting synthetic CpG ODNdue to the type I pro-inflammatory response it produces and its successful useas vaccine adjuvants.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2367
CpG Oligodeoxynucleotide Market –Dynamics
Increasing demand for vaccinationacross the globe is expected to contribute to significant growth of the CpGoligodeoxynucleotide market over the forecast period. For instance, accordingto the UNICEF-Vaccination & Immunization Statistics, in 2017, around 123million children got immunized with lifesaving vaccines across the world.Moreover, according to the Centers for Disease Control and Prevention (CDC), atleast 3,153,876,236 doses of vaccines were distributed in the U.S. from 2006 to2016.
Rising prevalence of new chronicdiseases and the demand for reducing the occurrence of childhood diseases suchas polio and others are expected to propel growth of the CpG oligodeoxynucleotidemarket. According to the Centers for Disease Control and Prevention (CDC),around 25.3 per 100,000 children die at the age of 1-4 years due to congenitalmalformations, deformations, and chromosomal abnormalities, and others.
CpG Oligodeoxynucleotide Market –Regional Insights
On the basis of geography, theglobal CpG oligodeoxynucleotide market is segmented into North America, Europe,Latin America, Asia Pacific, Middle East, and Africa. North America helddominant position in the global CpG oligodeoxynucleotide market in 2017. Thisis owing to high mortality due to various diseases such as pneumonia,diphtheria, pertussis, and others is expected to propel growth of the market inthis region. For instance, according to the Centers for Disease Control &Prevention (CDC), in 2016, around 48,632 children died from pneumonia, whichwas around 15.1 per 100,000 population in the U.S.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/cpg-oligodeoxynucleotide-market-2367
Moreover, Asia pacific isexpected to witness significant growth in the CpG oligodeoxynucleotide market,owing to rising focus on R&D along with mass manufacturing of cheap andaffordable vaccines in the region. For instance, according to the InternationalVaccine Institute (IVI), India became the new hub for vaccine research withover 60% of the world’s vaccines manufactured in India in 2016.
CpG Oligodeoxynucleotide Market –Competitive Landscape
Major players operating in theglobal CpG oligodeoxynucleotide market include Novus Biologicals, InvivoGen,Merck KGaA, Hycult Biotech, Miltenyi Biotec, Sapphire Bioscience, Biomol GmbH,and Cosmobio. Key players are focused on adopting market strategies such asmergers and acquisitions, and new product development, in order to retaindominant position in the market. For instance, in July 2014, Techne Corporationacquired Novus Biologicals, a Colorado-based supplier of outsourced andin-house developed antibodies for life science research, for around US$ 60 millionin cash.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2367
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
